pretations of the evidence on outcomes have resulted in various screening guidelines and debate regarding the balance of benefits and risks of mammography screening. 2 Part of this debate involves uncertainty about when to stop screening given that women 75 years or older were not included in randomized clinical trials, which limited the sources of most available data to small observational studies. 3, 4 This knowledge gap may be informed by new large-scale evidence from the National Mammography Database (NMD), a mammography outcomes database with current data from a large proportion of US states. 5 Using data from the NMD, we evaluated the association between patient age and screening mammography performance metrics in women 40 years or older. Table summarizes results of performance metrics by patient age. Overall, the mean recall rate is 9.6% (95% CI, 9.6%-9.7%), with a statistically significant decrease from 14.5% (95% CI, 14.4%-14.6%) in women aged 40 to 44 years to 6.1% (95% CI, 5.7%-6.5%) in women 2 and PPV 3 also significantly increased with age. These trends persisted in the longitudinal trend analysis of performance metrics over time (Figure) .
Methods
Discussion | The NMD provides current nationwide benchmarks for screening performance metrics. On the basis of increasing age, screening mammography performance metrics demonstrated not only a statistically significant upward trend for cancer detection rate (PPV) but also a statistically significant downward trend in recall rate with advancing age. These audit outcomes indicate no specific age cutoff point for screening. Increasingly favorable screening mammography performance metrics among women aged 75 to 90 years do not provide evidence for age-based mammography cessation; rather, it adds support for guidelines that encourage screening decisions among elderly women on the basis of individual patient values, comorbidities, and health status. Limitations of this study include its retrospective design, incomplete data on biopsy follow-up, lack of linkage to a tumor registry, and insufficient follow-up to determine if increased cancer detection reduced breast cancer mortality.
Conclusion | This study provides no audit-based evidence for age-based screening cessation and supports guidelines for encouraging screening on the basis of individual patient values, comorbidities, and health status. In Reply We understand and welcome the comments of Little and colleagues, and we agree that it would require a metaanalysis to demonstrate the utility of minimal residual disease (MRD) as a trial-level surrogate, looking at predicting between-arm differences in survival using between-arm differences in MRD status. 1 We do, however, believe that the magnitude of the MRD effects is sufficiently large as to encourage testing of its use as a surrogate. This is based not only on the evidence provided in the meta-analysis, but also on the fact that MRD seems to be specifically quantifying residual myeloma posttreatment, and so there is a biological underpinning to its use as a surrogate, because treatments are specifically designed to reduce this tumor burden. We have also previously demonstrated that it is not just MRD positivity or negativity that predicts subsequent outcome but the MRD level itself, 2 which would be a consequence of the fact that it is quantifying posttreatment residual disease. If it was possible to also measure MRD regrowth rates easily, progression-free survival (PFS) would then be uniquely determined.
